Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study

Calvo, Emiliano; Escudier, Bernard; Motzer, Robert J.; Oudard, Stéphane; Hutson, Thomas E.; Porta, Camillo; Bracarda, Sergio; Grünwald, Viktor; Thompson, John A.; Ravaud, Alain; Kim, D.; Panneerselvam, Ashok; Anak, Oezlem; Figlin, Robert A.

doi:10.1016/j.ejca.2011.11.027

Cited by 123 publications

(81 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Compared to BSC alone, everolimus plus BSC was associated with a 67% reduction in risk for disease progression (HR ¼ 0.33; p50.001) 14 . In the sub-group of patients previously treated with sunitinib as the only neoplastic therapy, everolimus treatment was associated with a median PFS of 4.6 months vs 1.8 months for BSC patients (HR ¼ 0.22; 95% CI ¼ 0.09-0.55) 15 . Axitinib, a tyrosine kinase inhibitor, has also recently been approved to treat advanced RCC after failure of prior systemic therapy 16 .…”

Section: Introductionmentioning

confidence: 99%

Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US

Perrin¹,

Sherman²,

Pal³

et al. 2014

Journal of Medical Economics

View full text Add to dashboard Cite

Objective: Everolimus and axitinib are approved in the US to treat patients with advanced renal cell carcinoma (RCC) after failure on sunitinib or sorafenib, and one prior systemic therapy (e.g., sunitinib), respectively. Two indirect comparisons performed to evaluate progression-free survival in patients treated with everolimus vs axitinib suggested similar efficacy between the two treatments. Therefore, this analysis compares the lifetime costs of these two therapies among sunitinib-refractory advanced RCC patients from a US payer perspective. Research design and methods:A Markov model was developed to simulate a cohort of sunitinib-refractory advanced RCC patients and estimate the cost of treating patients with everolimus vs axitinib. The following health states were included: stable disease without adverse events (AEs), stable disease with AEs, disease progression (PD), and death. The model included the following resources: active treatments, post-progression treatments, adverse events, physician and nurse visits, scans and tests, and palliative care. Resource utilization inputs were derived from a US claims database analysis. Additionally, a 3% annual discount rate was applied to costs, and the robustness of the model results was tested by conducting sensitivity analyses, including those on dosing scheme and post-progression treatment costs. Results:Base case results demonstrated that patients treated with everolimus cost an average of $12,985 (11%) less over their lifetimes than patients treated with axitinib. The primary difference in costs was related to active treatment, which was largely driven by axitinib's higher dose intensity. Results remained consistent across sensitivity analyses for AE and PD treatment costs, as well as dose intensity and discount rates. Conclusion:The results suggest that everolimus likely leads to lower lifetime costs than axitinib for sunitinib-refractory advanced RCC patients in the US.

show abstract

Section: Introductionmentioning

confidence: 99%

Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US

Perrin¹,

Sherman²,

Pal³

et al. 2014

Journal of Medical Economics

View full text Add to dashboard Cite

show abstract

“…In the subgroup of patients who received one TKI, median PFS in everolimus group was 5.4 months, and in group who received two TKI-s 4 months. This was statistically significant longer than in placebo groups, where PFS was 1.9 and 1.8 months respectively [8,20,[36][37][38].…”

Section: Mtor Inhibitor After First Line Vegf-tkimentioning

confidence: 96%

Changing Mechanisms of Action as a Strategy for Sequential Targeted Therapy of Metastatic Renal-Cell Carcinoma

Rajer¹

2013

Renal Tumor

View full text Add to dashboard Cite

“…Не-смотря на трудность сравнений между разными иссле-дованиями, значения ВБП, достигнутые при терапии эверолимусом в популяции пациентов с рефрактерно-стью к бевацизумабу, представляются довольно благо-Л И Т Е Р А Т У Р А приятными и сравнимыми даже с первой линией те-рапии (эверолимус (7,9 мес) или сунитиниб (10,7 мес)) [15]. Наши данные также говорят о том, что ингиби-рование mTOR после терапии бевацизумабом позво-ляет добиться более выраженного клинического эф-фекта по сравнению с ингибированием mTOR после таргетной терапии, действующей в отношении VEGFR (медиана ВБП 5,4 мес [16], частота ответов 1,8% [17]). …”

Section: материалы и методыunclassified

Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T⃰

et al. 2015

View full text Add to dashboard Cite

Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study

Cited by 123 publications

References 19 publications

Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US

Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US

Changing Mechanisms of Action as a Strategy for Sequential Targeted Therapy of Metastatic Renal-Cell Carcinoma

Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T⃰

Contact Info

Product

Resources

About